Jon has been reporting on stock markets for over twenty-five years for audio text companies (remember them?!), newswires, and websites. He helped set up MarketEye News for ICV/Topic in the 1990’s before moving on to become a Markets reporter at AFX News. After over 10 years, which saw him rise to the dizzy heights of Markets Editor at AFX, the firm’s acquisition by Thomson Corp and subsequent takeover of Reuters, he moved on in 2012. Prior to Proactive Investors, he was News Editor for thisismoney.co.uk, the Mail Online’s financial website.
The letter, addressed to Debenhams CEO Sergio Bucher, and published by the Daily Telegraph, suggests without the money the retailer "has zero chance of survival"
Peel Hunt’s analysts said: “Today’s figures were solid given the circumstances but we have run out of patience with the lack of visibility on strategy"
Barclays' analysts said while they consider a premium valuation to be appropriate at this point in the cycle, on their 2019 price/earnings of 13.8x they think Sabre appears expensive versus their peers
Founded in 1994, Compuscan is one of the leading providers of credit information and decision analytics in South Africa, with operations across seven key geographies in Sub-Saharan Africa
The AIM-listed mining company, with operating mines in Romania as well as Zimbabwe, said it will update the market as soon as it receives official notification
The bank hiked its target for the FTSE 100-listed stock by 4% to 2,600p, up from 2.500p previously, with its shares currently trading at 2,435p, down 0.1% on yesterday’s close
The study, being initiated at Helsinki and Oulu University Hospitals in Finland, is a first-in-human open-label phase I/II clinical trial to investigate the safety and efficacy of Clevegen in selected metastatic or inoperable solid tumours
The US investment bank set a price target of 1,460p on the FTSE 100-listed firm, with Glaxo's shares trading at 1,476.20p late morning, down 0.4% on Thursday’s closing price